Survodutide
Also known as: BI 456906, Glucagon/GLP-1 dual agonist
Investigational dual glucagon and GLP-1 receptor agonist for obesity and metabolic dysfunction-associated steatohepatitis (MASH).
Evidence
Emerging
FDA status
Not FDA-approved
Source
Synthetic glucagon/GLP-1 dual agonist
Overview
Investigational dual glucagon and GLP-1 receptor agonist for obesity and metabolic dysfunction-associated steatohepatitis (MASH).
Mechanism of Action
Dual agonist of glucagon and GLP-1 receptors, increases energy expenditure and fat oxidation via glucagon pathway, reduces appetite and improves insulin secretion via GLP-1, targets liver fat reduction and metabolic health.
What research has looked at
Effects reported in studies, not proven benefits. See the evidence section below for how strong the research is.
- Weight loss (trials)
- Liver fat (trials)
- Increases energy expenditure
- Improved metabolic parameters
- Appetite suppression
- Liver scarring (trials)
Researched for
Research topics, not approved uses.
How Gabriel approaches peptides
Through Gabriel, licensed clinicians may prescribe BPC-157, TB-500, MOTS-c, epitalon and semax (nasal) as compounded medications from licensed 503A pharmacies, under HHS's October 28, 2026 interim policy, and only when appropriate. They are not FDA-approved, and Gabriel never gives peptide dosing. Survodutide isn't prescribed through Gabriel. If you're thinking about it, Gabriel can help you find a licensed clinician to look at the cause of what you're dealing with and the options with stronger evidence.
Research & Evidence
Phase 2 trials for obesity and MASH
Phase 2 and phase 3 trials reported weight loss and lower liver fat. As of October 2026 it is not FDA-approved.
Safety Information
Potential Side Effects
- •Nausea
- •Diarrhea
- •Vomiting
- •Injection site reactions
- •Elevated heart rate (mild)
Contraindications
- Under investigation
Interactions
- ⚠Under investigation
Quick Facts
Related Peptides
AOD-9604
Growth hormone fragment that promotes fat loss through lipolysis without affecting IGF-1 or glucose.
Semaglutide
Weekly GLP-1 receptor agonist, FDA-approved as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for weight management and other uses.
Tirzepatide
Weekly GIP and GLP-1 receptor agonist, FDA-approved as Mounjaro for type 2 diabetes and as Zepbound for weight management and obstructive sleep apnea.